Intranasal Anti-Cd3 Mab Treatment Showed A Reduction In Intracerebral Hemorrhage Injury Severity
27/04/2023 12:15
April 27 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES LTD - INTRANASAL ANTI-CD3 MAB
TREATMENT
SHOWED A REDUCTION IN INTRACEREBRAL HEMORRHAGE INJURY SEVERITY
Source text for Eikon: ID:nGNX6N1l3T
Further company coverage: TLSA.O
(Reporting by Siddarth S)
((Siddarth.s@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study